Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

Research output: Contribution to journalReviewResearchpeer-review

Standard

Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. / Vollesen, Anne Luise Haulund; Amin, Faisal Mohammad; Ashina, Messoud.

In: Neurotherapeutics, Vol. 15, No. 2, 2018, p. 371-376.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Vollesen, ALH, Amin, FM & Ashina, M 2018, 'Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine', Neurotherapeutics, vol. 15, no. 2, pp. 371-376. https://doi.org/10.1007/s13311-017-0596-x

APA

Vollesen, A. L. H., Amin, F. M., & Ashina, M. (2018). Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. Neurotherapeutics, 15(2), 371-376. https://doi.org/10.1007/s13311-017-0596-x

Vancouver

Vollesen ALH, Amin FM, Ashina M. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. Neurotherapeutics. 2018;15(2):371-376. https://doi.org/10.1007/s13311-017-0596-x

Author

Vollesen, Anne Luise Haulund ; Amin, Faisal Mohammad ; Ashina, Messoud. / Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. In: Neurotherapeutics. 2018 ; Vol. 15, No. 2. pp. 371-376.

Bibtex

@article{9d2b69e3d9db4b38bb06b04671181338,
title = "Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine",
author = "Vollesen, {Anne Luise Haulund} and Amin, {Faisal Mohammad} and Messoud Ashina",
year = "2018",
doi = "10.1007/s13311-017-0596-x",
language = "English",
volume = "15",
pages = "371--376",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

AU - Vollesen, Anne Luise Haulund

AU - Amin, Faisal Mohammad

AU - Ashina, Messoud

PY - 2018

Y1 - 2018

U2 - 10.1007/s13311-017-0596-x

DO - 10.1007/s13311-017-0596-x

M3 - Review

C2 - 29464574

VL - 15

SP - 371

EP - 376

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -

ID: 216508970